Mutations in IL-1R Gene Linked To A Variety of Diseases (G3659)

Target Name: IRF1

NCBI ID: G3659

IRF1

Mutations in IL-1R Gene Linked To A Variety of Diseases

The interleukin-1 receptor (IL-1R) is a protein that plays a crucial role in the regulation of immune and inflammatory responses. Mutations in the IL-1R gene have been linked to a variety of diseases, including autoimmune disorders, chronic pain, and cancer. One of the most well-studied mutations is the IL-1 receptor variant 1 (IRF1), which is a common mutation that has been found in a wide range of diseases. In this article, we will discuss IRF1, its role in disease, and its potential as a drug target.

The IL-1R gene is a member of the Interleukin-1 receptor family, which is a group of cytokines that play a key role in the regulation of immune and inflammatory responses. The IL-1R gene encodes a protein that consists of an extracellular domain , a transmembrane domain, and an intracellular domain. The extracellular domain of IL-1R is responsible for the formation of the IL-1 receptor complex, which consists of the IL-1 receptor alpha chain and the associated adapter protein.

Mutations in the IL-1R gene have been linked to a wide range of diseases, including autoimmune disorders, chronic pain, and cancer. One of the most well-studied mutations is the IRF1 gene, which is a common mutation that has been found in a wide range of diseases, including rheumatoid arthritis, psoriasis, and chronic pain.

The IRF1 gene is located on chromosome 12q22 and has been studied extensively in the context of autoimmune diseases. Studies have shown that individuals with a family history of autoimmune diseases are more likely to have a mutation in the IRF1 gene. In addition, genetic studies have shown that the IRF1 gene is involved in the regulation of immune responses and that mutations in the gene are associated with an increased risk of developing autoimmune diseases.

In addition to its role in autoimmune diseases, the IRF1 gene has also been linked to the development of other diseases. For example, studies have shown that individuals with a family history of cancer are more likely to have a mutation in the IRF1 gene. In In addition, genetic studies have shown that the IRF1 gene is involved in the regulation of cell growth and that mutations in the gene are associated with an increased risk of developing cancer.

The potential implications of a mutation in the IRF1 gene are significant, as it is involved in the regulation of both immune and cancer-related processes. In addition, the IRF1 gene has also been implicated in the development of chronic pain, which can have a significant impact on an individual's quality of life.

Despite the potential implications of a mutation in the IRF1 gene, research into the its role and potential as a drug target is still in its infancy. While a number of studies have identified the IRF1 gene as a potential drug target, more research is needed to determine its role in disease and its potential as a therapeutic intervention.

The Role of IRF1 in Disease

The IRF1 gene has been linked to a wide range of diseases, including autoimmune disorders, chronic pain, and cancer. In addition to its role in these diseases, the IRF1 gene has also been implicated in the regulation of immune responses, cell growth, and the development of cancer.

One of the most well-studied mutations is the IRF1 gene, which is a common mutation that has been found in a wide range of diseases, including rheumatoid arthritis, psoriasis, and chronic pain. Studies have shown that individuals with a family history of autoimmune diseases are more likely to have a mutation in the IRF1 gene. In addition, genetic studies have shown that the IRF1 gene is involved in the regulation of immune responses and that mutations in the gene are associated with an increased risk of developing autoimmune diseases.

In addition to its role in autoimmune diseases, the IRF1 gene has also been linked to the development of other diseases. For example, studies have shown that individuals with a family history of cancer are more likely to have a mutation in the IRF1 gene. In In addition, genetic studies have shown that the IRF1 gene is involved in the regulation of cell growth and that mutations in the gene are associated with an increased risk of developing cancer.

The potential implications of a mutation in the IRF1 gene are significant, as it is involved in the regulation of both immune and cancer-related processes. In addition, the IRF1 gene has also been implicated in the development of chronic pain, which can have a significant impact on an individual's quality of life.

Despite the potential implications of a mutation in the IRF1 gene, research into its role in disease is still in its infancy. While a number of studies have identified the IRF1 gene as a potential drug target, more research is needed to determine its role in disease and its potential as a therapeutic intervention.

The Potential as a Drug Target

The IRF1 gene has been identified as a potential drug target due to its involvement in the regulation of both immune and cancer-related processes. In addition, the IRF1 gene has also been shown to be involved in the regulation of cell growth, which could provide insight into its potential as a therapeutic intervention.

One potential approach to targeting the IRF1 gene is to use small molecules, such as drugs that can modulate the activity of the IRF1 receptor. This approach would allow researchers to study the role of the IRF1 gene in disease and to identify potential therapeutic interventions.

Another potential approach to targeting the IRF1 gene is to use antibodies that can recognize and target specific mutations in the gene. This approach would allow researchers to study the role of the IRF1 gene in disease and to identify potential therapeutic interventions.

While the potential as a drug target for the IRF1 gene is an exciting area of 鈥嬧?媟esearch, it is important to remember that much more research is needed. While a number of studies have identified the IRF1 gene as a potential drug target, more research is needed to determine its role in disease and its potential as a therapeutic intervention.

Conclusion

The interleukin-1 receptor (IL-1R) is a protein that plays a crucial role in the regulation of immune and inflammatory responses. Mutations in the IL-1R gene have been linked to a variety of diseases, including autoimmune disorders, chronic pain, and cancer. One of the most well-studied mutations is the IL-1 receptor variant 1 (IRF1), which is a common mutation that has been found in a wide range of diseases. In this article, we have discussed the role of IRF1 in disease, its potential as a drug target, and the implications of a mutation in the gene.

While the potential as a drug target for the IRF1 gene is an exciting area of 鈥嬧?媟esearch, it is important to remember that much more research is needed. While a number of studies have identified the IRF1 gene as a potential drug target, more research is needed to determine its role in disease and its potential as a therapeutic intervention.

The IRF1 gene has been linked to a wide range of diseases, including autoimmune disorders, chronic pain, and cancer. In addition to its role in these diseases, the IRF1 gene has also been implicated in the regulation of immune responses, cell growth, and the development of cancer. While the potential as a drug target for the IRF1 gene is an exciting area of 鈥嬧?媟esearch, more research is needed to determine its role in disease and its potential as a therapeutic intervention.

Protein Name: Interferon Regulatory Factor 1

Functions: Transcriptional regulator which displays a remarkable functional diversity in the regulation of cellular responses (PubMed:15226432, PubMed:15509808, PubMed:17516545, PubMed:17942705, PubMed:18497060, PubMed:19404407, PubMed:19851330, PubMed:22367195, PubMed:32385160). Regulates transcription of IFN and IFN-inducible genes, host response to viral and bacterial infections, regulation of many genes expressed during hematopoiesis, inflammation, immune responses and cell proliferation and differentiation, regulation of the cell cycle and induction of growth arrest and programmed cell death following DNA damage (PubMed:15226432, PubMed:15509808, PubMed:17516545, PubMed:17942705, PubMed:18497060, PubMed:19404407, PubMed:19851330, PubMed:22367195). Stimulates both innate and acquired immune responses through the activation of specific target genes and can act as a transcriptional activator and repressor regulating target genes by binding to an interferon-stimulated response element (ISRE) in their promoters (PubMed:15226432, PubMed:15509808, PubMed:17516545, PubMed:17942705, PubMed:18497060, PubMed:19404407, PubMed:19851330, PubMed:21389130, PubMed:22367195). Competes with the transcriptional repressor ZBED2 for binding to a common consensus sequence in gene promoters (PubMed:32385160). Its target genes for transcriptional activation activity include: genes involved in anti-viral response, such as IFN-alpha/beta, RIGI, TNFSF10/TRAIL, ZBP1, OAS1/2, PIAS1/GBP, EIF2AK2/PKR and RSAD2/viperin; antibacterial response, such as GBP2, GBP5 and NOS2/INOS; anti-proliferative response, such as p53/TP53, LOX and CDKN1A; apoptosis, such as BBC3/PUMA, CASP1, CASP7 and CASP8; immune response, such as IL7, IL12A/B and IL15, PTGS2/COX2 and CYBB; DNA damage responses and DNA repair, such as POLQ/POLH; MHC class I expression, such as TAP1, PSMB9/LMP2, PSME1/PA28A, PSME2/PA28B and B2M and MHC class II expression, such as CIITA; metabolic enzymes, such as ACOD1/IRG1 (PubMed:15226432, PubMed:15509808, PubMed:17516545, PubMed:17942705, PubMed:18497060, PubMed:19404407, PubMed:19851330, PubMed:22367195). Represses genes involved in anti-proliferative response, such as BIRC5/survivin, CCNB1, CCNE1, CDK1, CDK2 and CDK4 and in immune response, such as FOXP3, IL4, ANXA2 and TLR4 (PubMed:18641303, PubMed:22200613). Stimulates p53/TP53-dependent transcription through enhanced recruitment of EP300 leading to increased acetylation of p53/TP53 (PubMed:15509808, PubMed:18084608). Plays an important role in immune response directly affecting NK maturation and activity, macrophage production of IL12, Th1 development and maturation of CD8+ T-cells (PubMed:11244049, PubMed:11846971, PubMed:11846974, PubMed:16932750). Also implicated in the differentiation and maturation of dendritic cells and in the suppression of regulatory T (Treg) cells development (PubMed:11244049, PubMed:11846971, PubMed:11846974, PubMed:16932750). Acts as a tumor suppressor and plays a role not only in antagonism of tumor cell growth but also in stimulating an immune response against tumor cells (PubMed:20049431)

The "IRF1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IRF1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets